CD5 antigen-like Antibodies

CD5 antigen-like (CD5L)

Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflammed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Following incorporation into mature adipocytes via CD36-mediated endocytosis, partners with cytosolic FASN, inhibiting fatty acid synthase activity and resulting in lipolysis, the degradation of triacylglycerols to glycerol and free fatty acids (FFA).

CD5L-induced lipolysis occurs with development of obesity: participates in obesity-associated inflammation after recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity- related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC).

Gene Information

Human
Gene Name:	CD5L
Uniprot:	O43866
Entrez:	922

Family

Belongs to:
No superfamily

Alternative Names

AIM; API6; apoptosis inhibitor 6; CD5 antigen-like (scavenger receptor cysteine rich family); CD5 antigen-like; CD5 molecule-like; CD5L; CT-2; IgM-associated peptide; PRO229; Spalpha; SP-alpha

Molecular Weight

Mass (kDA):
38.088 kDA

Genomic Context

Human
Location:	1q23.1
Sequence:	1; NC_000001.11 (157827068..157841844, complement)

Tissue Specificity

Expressed in spleen, lymph node, thymus, bone marrow, and fetal liver, but not in non-lymphoid tissues.

Subcellular Localizations

Secreted. Cytoplasm. Secreted by macrophages and circulates in the blood (PubMed:24223991, PubMed:24804991). Transported in the cytoplasm via CD36-mediated endocytosis (By similarity).

Diseases

• Inflammation
• Pneumonia
• Metabolic Diseases
• Obesity
• Lung Diseases
• Malignant Neoplasms
• Liver Cirrhosis
• Hepatitis C, Chronic
• Fibrosis
• Pulmonary Emphysema
• Lymphoma
• Chronic Inflammation
• Hepatitis

• Hepatitis C
• Lung Injury
• Liver Diseases
• Gram-positive Bacterial Infections
• Insulin Resistance
• Innate Immune Response
• Tissue Adhesions

Pathways

• Pathogenesis
• Cell Growth
• Secretion
• Cell Activation
• Cell Proliferation
• T Cell Activation
• Immune Response
• B Cell Proliferation
• Cell Adhesion
• Chemokine Production
• Glycosylation
• Dna Repair
• Endocytosis

• Inflammatory Response
• Immunoglobulin Secretion
• Translation
• Cell Death
• Cell Cycle
• Innate Immune Response
• Regulation Of T Cell Activation

PTMs

• Phosphorylation

• Glycosylation

• Cleavage

Research Areas

• Apoptosis

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CD5L

Best Uses Of The CD5L Marker

CD5L is an antibody with an affinity for CD5L that is high. Boster scientists are able to submit the results of their research to be used for purposes of species and application. These results are considered suitable for product credits and are accessible to scientists around the world. This article will concentrate on the advantages of CD5L marker-based biomarkers. It also discusses the use of high-affinity prima antibodies.

Optimization

If you're a researcher, you know that there are a variety of ways to use the CD5L marker. However the CD5L immunoblot is only useful when you have an end-point in mind. A CD5L antibody can be used to determine whether cancer cells are carrying the gene.

Benefits

The CD5L marker can be used to develop more effective treatments for patients suffering from HCC. It allows for targeted and individual therapy. This marker is being used to study cancerous cells and tumors in patients suffering from HCC. Here's an review of CD5L. In addition to its benefits in clinical practice CD5L is also associated with other diseases. For instance, it may aid in determining the risk of developing a specific type of cancer.

One of the major functions of CD5L lies in the differentiation of macrophages. It is the reason for the M2 macrophage phenotype. CD5L is not shown to increase tumorigenesis , or other inflammatory diseases. It also has an impact on the immune system, by encouraging wound healing. It is also connected to inflammation reactions that include the reduction or elimination of pain.

The benefits of CD5L the treatment of cancer cells are numerous. In one study, CD5L treatment increased the number of FITC-positive macrophages however no effect was observed in the untreated group. In a parallel study THP1 macrophages treated with rCD5L showed expression of IL10 or DXM. The results of these studies point to the benefits of CD5L as a marker for inflammatory conditions.

The CD5L marker is anti-inflammatory and pro-autophagy properties in macrophages. It increased the levels of LysoTracker red and LC3 puncta in monocytes from THP1. ATG7-silencing decreased the levels of LC3–LR in THP1HsCD5L monocytes. CD5L also stimulated IL10 production. CD5L could also be involved in the processing IL10 protein in MF, as evidenced by the increase in autophagosome content.

Use high-affinity primary antibody

Utilizing high-affinity primary antibodies is a fantastic way to boost the success of your research. As the name suggests, affinity refers to the strength of binding between a particular protein and the ligand. The degree of affinity can be determined by measuring the equilibrium disociation value (KD) which measures the rate at which a molecular is dissociated from its constituent parts. KD is measured by comparing the off - and on-rates of a reaction and a lower value indicates more affinity.

High-affinity primary antibodies are those that have an extremely high binding affinity and specificity to a target protein. These antibodies are made by using S25-2 primers which isolate the variable genes. The primary antibodies were evaluated against other antibodies with known structure. This is a fantastic way to confirm the specificity of an antibody in the sample. Primary antibodies with high affinity are not suitable for all situations.

In addition to maximizing the affinity of serum antibodies, these high-affinity AFCs can also be utilized in the production of different types of antibodies. The GC B-cell population undergoes affinity maturation after the initial immunization. To find out this, serum samples from a group of animals were collected at regular intervals and analyzed for total IgG1 titre and high-affinity NP specific IgG1 titre. The results showed that high-affinity antibodies were highest at the beginning of day seven and slowly increased as time passed until animals reached 21 days.

GC/memory B cells exhibit distinct affinity maturation processes in comparison to AFCs. The proportion of high-affinity antibody-producing cells in GC B cells grows more modified. However this does not increase the number of memory B cells. AFCs secret a high-affinity antibody starting at day six in the spleen. It increases gradually to 100% by day 28 in the bone marrow.